A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the tumor suppressor p53 gene—found very frequently in human tumors—hijack DNA ...

The gene p53 acts as a tumor suppressor and often is called the ‘guardian of the genome.’ This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading ...

Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator ...

A research team at the University of Konstanz, led by toxicologist Ivano Amelio, has demonstrated how differently individual mutations of the tumor suppressor p53 affect pancreatic carcinomas. When ...

Cancer arises when your cells grow uncontrollably and refuse to die when they should. Normally, your body is equipped with regulatory processes to prevent this chaos. One such mechanism involves a ...

In a recent perspective published in the journal Cell Death and Differentiation, researchers in France, Germany, and Sweden discussed the unique mutational spectrum of the transformation-related ...

TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...

Approximately 25-30% of lung cancer patients lack mutations targeted by current therapies, necessitating novel approaches. New targets, including MTAP deletions, SMARC4, and p53 mutations, show ...

Investigators at Cold Spring Harbor Laboratory say they've identified a biomarker that can quickly highlight a potentially deadly mutation in p53, a natural tumor suppressor. They found that the ...

Autologous T-Cell Therapies in Solid Tumor Malignancies: Current Landscape and Future Opportunities Histology-agnostic therapies: by focusing on common mutations across various cancers, this approach ...